Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Post by narmacon Jan 24, 2022 12:18pm
371 Views
Post# 34353360

Dr. M. Sweeney interview on CHQR!

Dr. M. Sweeney interview on CHQR!Somewhat of a waste of time. Too deep for the layperson imo. The Dr. I think has C19 based on his inability to stop a throat cough.  Should have taken a rapid test before the studio setting. Too bad,,, hope he recovers soon. Somewhat of a different time frame given around ABLs availability to the public if all goes as planned vs Pinocchio's unrealistic sale pitches.

But,,at least we had a new voice to listen to. My spine didnt shiver on the audio!,,,,did note that he believes ABL will work for all variants of this C19 virus!,,great to hear!

The science is so compelling,,,however,,,,,the business side is such a disaster!!!
<< Previous
Bullboard Posts
Next >>